UNSPSC 51111781: Olaparib

Olaparib is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.

UNSPSC 51111781 Olaparib, a Commodity code, shows no relevant recent state and local procurement activity. The source records include only one opportunity explicitly coded to this pharmaceutical product: Seminole County, Florida's June 2026 IFB for Naloxone and Safe Drug Deactivation Systems—a distinct product class unrelated to olaparib, a PARP inhibitor used in oncology treatment. The remaining opportunities in the dataset span reverse trade shows, vendor networking events, pharmaceutical wholesaling cooperatives, medical oxygen rental, clinic and wellness services, forensic drug standards, and opioid settlement grants across Florida, Texas, Arizona, Minnesota, and other states. None of these solicitations procure olaparib or reference it by name or therapeutic indication. The code itself may be underutilized in state and local procurement systems, or jurisdictions may classify cancer-treatment pharmaceuticals under broader pharmaceutical supply codes rather than granular NDC-specific taxonomy. Without evidence of active olaparib solicitations, the code does not present a clear market signal for business development pursuit at this time.

The mismatch between the code's specificity and recent procurement activity suggests that state and local buyers acquire this product—if at all—through standing pharmaceutical contracts, formulary agreements, or oncology-specific group purchasing organizations (GPOs) rather than through discrete UNSPSC-coded solicitations. Vendors pursuing oncology pharmaceutical supply in the state and local sector should monitor higher-tier pharmaceutical codes and cooperative purchasing vehicles such as MMCAP (Minnesota Multistate Cooperative Purchasing Alliance), which establishes multi-state generic and brand pharmaceutical contracts, rather than anticipate direct RFP activity under this commodity code.